Mollie McGuire
Primary Care · Johnstown, PANPI 1922573435
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.0% of the total across 537 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 24 manufacturers reported payments, led by AstraZeneca at 30.8% of the total. Among primary care clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 537 payments — averaging $21.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$4K
- GSK$2K
- Regeneron Healthcare Solutions, Inc.$1K
- Sanofi$829
- Boehringer Ingelheim$792
- Amgen$765
- plus $3K from 18 others
What the payments were for
- Food & beverage$11,05597%
- Education$3403%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 129 | $3,511 |
| GSK | 133 | $1,778 |
| Regeneron Healthcare Solutions, Inc. | 42 | $1,160 |
| Sanofi | 44 | $829 |
| Boehringer Ingelheim | 22 | $792 |
| Amgen | 39 | $765 |
| Actelion Pharmaceuticals US, Inc. | 33 | $712 |
| Mylan Specialty L.p. | 11 | $296 |
| Grifols USA, LLC | 14 | $285 |
| Philips North America LLC | 11 | $185 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $167 |
| Insmed, Inc. | 10 | $165 |
| Baxter Healthcare | 7 | $140 |
| AbbVie | 8 | $125 |
| Viatris Specialty LLC | 6 | $117 |
| Sanofi-aventis U.S. LLC | 1 | $100 |
| Harmony Biosciences LLC | 3 | $59 |
| Gilead | 3 | $48 |
| Novartis | 3 | $48 |
| Electromed, Inc. | 6 | $42 |
| Pulmonx Corporation | 1 | $20 |
| United Therapeutics Corporation | 1 | $17 |
| Vifor Pharma, Inc. | 1 | $17 |
| Jazz Pharmaceuticals Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,395 in reported general payments places this provider in the 95th percentile of 300 primary care providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 1,065 | $783,506 |
| Dupixent PenDupilumab | 83 | $324,851 |
| Dupixent SyringeDupilumab | 32 | $135,494 |
| TezspireTezepelumab-Ekko | 24 | $100,370 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 127 | $83,130 |
| NucalaMepolizumab | 12 | $44,117 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 70 | $38,593 |
| Breo ElliptaFluticasone/Vilanterol | 74 | $33,341 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 34 | $20,990 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 79 | $15,179 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 356 | $12,588 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 65 | $11,677 |
| Varenicline Tartrate | 42 | $11,534 |
| Ventolin HfaAlbuterol Sulfate | 168 | $10,641 |
| SymbicortBudesonide/Formoterol Fumarate | 32 | $8,683 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta | $1,778 | $902,7491,232 claims |
| AstraZenecaTezspire, Breztri Aerosphere, Symbicort, Bevespi Aerosphere | $3,511 | $197,555195 claims |
| Boehringer IngelheimStiolto Respimat | $792 | $20,99034 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 300 primary care providers in Pennsylvania.
Other primary care in Johnstown
- Jule LesneskiJohnstown$6K
- Cheryl StapeJohnstown$4K
- Kersten ReiderMount Penn$121K
- Teresa GiamboyPhiladelphia$21K
- Nicole IlgenfritzBethel Park$18K
- Galyna VorokhibPhiladelphia$12K
- Melissa BeansWarrington$12K
- Andrea MauriceNew Cumberland$11K
- Kendell SoglieroSmithfield$9K
- Minjung RegerDoylestown$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.